From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4309-4318

  Zhu, Jiuxiang ^a   Huang, Jui Wen ^a   Tseng, Ping Hui ^a   Yang, Ya Ting ^a   Fowble, Joseph ^a   Shiau, Chung Wai ^a   Shaw, Yeng Jeng ^a   Kulp, Samuel K ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; OSU 03012; OSU 03013; PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR MODEL; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

CELL DIVISION; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 3042562279     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-4063     Document Type: Article

References (39)

1. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
2. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
3. Johnson AJ, Song X, Hsu A, Chen C. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 2001;41:221-35.
4. Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.
5. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94:1745-57.
6. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
7. Arico S, Pattingre S, Bauvy C, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002;277:27613-21.
8. Kulp SK, Yang YT, Hung CC, et al. PDK-1/Akt signaling represents a major COX-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
9. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
10. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014.
11. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 2001;268:487-98.
12. Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell 2000;103:185-8.
13. Storz P, Toker A. 3′-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci 2002;7:d886-902.
14. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
15. Cantley LC. The phosphoinositide 3-kinase pathway, Science 2002;296:1655-7.
16. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
17. Downes CP, Bennett D, McConnachie G, et al. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans 2001;29:846-51.
18. Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase signalling. Cell Signalling 2002;14:285-95.
19. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002;70:829-44.
20. Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D. Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol 2000;10:1439-42.
21. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998;19:1639-62.
22. Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93:79-98.
23. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
24. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
25. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-8.
26. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000;60(Suppl 1):25-32; discussion 41-22.
27. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8.
28. Prade L, Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997;5:1627-37.
29. Davies TG, Bentley J, Arris CE, et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 2002;9:745-9.
30. Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4- anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002;45:1300-12.
31. Biondi RM, Komander D, Thomas CC, et al. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J 2002;21:4219-28.
32. Juffer AH, Eisenhaber F, Hubbard SJ, Walther D, Argos P. Comparison of atomic solvation parametric sets: applicability and limitations in protein folding and binding. Protein Sci 1995;4:2499-509.
33. Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707-10.
34. Martin KA, Schalm SS, Richardson C, Romanelli A, Keon KL, Blenis J. Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. J Biol Chem 2001;276:7884-91.
35. Gonzalez-Garcia A, Garrido E, Hernandez C, et al. A new role for the p85-phosphatidylinositol 3- kinase regulatory subunit linking FRAP to p70 S6 kinase activation. J Biol Chem 2002;277:1500-8.
36. Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 2003;278:25872-8.
37. Wick MJ, Dong LQ, Riojas RA, Ramos FJ, Liu F. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3- phosphoinositide-dependent protein kinase-1. J Biol Chem 2000;275:40400-6.
38. Meier R, Thelen M, Hemmings BA. Inactivation and dephosphorylation of protein kinase Balpha (PKBalpha) promoted by hyperosmotic stress. EMBO J 1998;17:7294-303.
39. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, Van Aalten DM. Structural basis for UCN-01 specificity and PDK1 inhibition. Biochem. J. 2003:255-62.